SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/30/2016 5:51:06 PM - Followers: 59 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Small Company Offering and Sale of Securities Without Registration (d) 09/28/2016 01:59:39 PM
GALT News: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients ... 09/27/2016 04:15:00 PM
GALT News: Current Report Filing (8-k) 09/27/2016 04:12:20 PM
GALT News: Notice of Effectiveness (effect) 09/12/2016 06:02:07 AM
GALT News: Securities Registration Statement (simplified Form) (s-3/a) 08/31/2016 05:02:39 PM
PostSubject
#2499   I would strongly suggest you send some feedback gss2003 09/30/16 05:51:06 PM
#2498   Phase 1 certainly is about safety and that thefamilyman 09/30/16 05:12:05 PM
#2497   just curious, why are you convinced more than gss2003 09/30/16 01:31:20 PM
#2496   Let me say that Phase I is safety Chess Master 09/30/16 01:16:17 PM
#2495   send this suggestion to them via their website. gss2003 09/30/16 08:49:06 AM
#2494   I agree. I wonder how difficult/expensive it would thefamilyman 09/29/16 08:02:35 PM
#2493   The 8mg/kg was supposedly comparable to what was gss2003 09/29/16 04:51:01 PM
#2492   Clear to you me and the rest of Chess Master 09/29/16 04:25:24 PM
#2491   Here’s Why These Two Small Cap Biotechs Just trendmkr 09/29/16 04:05:38 PM
#2490   A picture of Galectin CEO before yesterday conference RottenandDemented 09/29/16 08:58:28 AM
#2489   Phase II Trial or Phase II Trolling? RottenandDemented 09/28/16 11:15:35 PM
#2488   It's clear Galt got the frequency and dosage rickyricks 09/28/16 10:42:18 PM
#2487   Traders and gamblers, hoping for a bounce like Dr_Thorfin 09/28/16 03:05:29 PM
#2486   Well, GALT failed, this is good for CNAT staccani 09/28/16 02:58:46 PM
#2485   Over 6 million shares traded. Who's buying? jmh0602 09/28/16 01:52:12 PM
#2484   if this thing's a total failure like it gss2003 09/28/16 01:30:43 PM
#2483   I will keep on Galectin the following months RottenandDemented 09/28/16 11:48:56 AM
#2482   Agree, just hard to believe if it has gss2003 09/28/16 11:41:25 AM
#2481   There is a little chance of success due RottenandDemented 09/28/16 11:40:58 AM
#2480   Of course but what good does it do biotech2010 09/28/16 11:30:08 AM
#2479   Also, if the interim results are positive why gss2003 09/28/16 11:27:46 AM
#2478   They haven't released the data but the Phase biotech2010 09/28/16 11:27:28 AM
#2477   Yes, but even Cohort 3 showed fibrosis benefits gss2003 09/28/16 11:24:00 AM
#2476   They have good data from the Phase 1 biotech2010 09/28/16 11:18:33 AM
#2475   It's a lifeline, with very little chance of gss2003 09/28/16 11:11:52 AM
#2474   Sell now or die tomorrow. RottenandDemented 09/28/16 11:07:37 AM
#2473   The company is worthless without success in the biotech2010 09/28/16 11:06:09 AM
#2472   Melanoma results could come by year end, that's IRAHopeful 09/28/16 11:05:31 AM
#2471   The company is valued at < $50M now, gss2003 09/28/16 10:59:32 AM
#2470   If the CX trial fails the company is biotech2010 09/28/16 10:54:45 AM
#2469   It sounds like they were going to consider gss2003 09/28/16 10:49:59 AM
#2468   Traber said on the conference call yesterday that biotech2010 09/28/16 10:44:47 AM
#2467   I think success would be more attributable to gss2003 09/28/16 10:08:17 AM
#2466   Buying! Data was only for 4 months, you biotechnician 09/28/16 10:00:16 AM
#2465   U r dilusional. But carry on believing in TrendTrade2016 09/28/16 04:45:40 AM
#2464   I want to see the blood tests. There Adi2 09/28/16 04:31:17 AM
#2463   That was a trial. Trial sometimes meet primary staccani 09/28/16 12:30:33 AM
#2462   GALT is the Sham-Wow of stocks. Plenty jasonrmh 09/27/16 10:29:08 PM
#2461   I have wondered why the Phase 1 did thefamilyman 09/27/16 09:51:10 PM
#2460   As a long term investor in GALT with JERZYATP1 09/27/16 08:12:58 PM
#2459   But there is a very little chance to success: RottenandDemented 09/27/16 07:54:23 PM
#2458   Galectin is rubbish. You can't cure hepatic cirrosis RottenandDemented 09/27/16 07:48:58 PM
#2457   Yes, but do we know if Ph II gss2003 09/27/16 07:35:29 PM
#2456   The FDA may view...? To be sure thefamilyman 09/27/16 07:29:50 PM
#2455   These are two very good points... thefamilyman 09/27/16 07:20:32 PM
#2454   How are those fundementals looking. Charts son is TrendTrade2016 09/27/16 07:13:05 PM
#2453   A couple things, i think I'll email IR too gss2003 09/27/16 06:23:06 PM
#2452   The CX trial is the last chance for biotech2010 09/27/16 06:08:49 PM
#2451   Galectin now worths near 0$ RottenandDemented 09/27/16 05:41:32 PM
#2450   Unless there are some interim results on the gss2003 09/27/16 05:30:08 PM
PostSubject